Epstein-Barr virus latent membrane protein 1 peptide-major histocompatibility complex class I complex (EBV LMP1-pMHC) (EBV LMP1-pMHC)

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) peptide-major histocompatibility complex (MHC) class I complexes are cell-surface targets formed by the presentation of intracellular viral fragments to the immune system. LMP1 is a potent oncogene expressed in EBV-associated malignancies, including nasopharyngeal carcinoma and various lymphomas, where it mimics CD40 signaling to promote cell survival and proliferation (Young & Rickinson, 2004). Because LMP1 is an intracellular or transmembrane protein, it is not directly accessible to conventional antibodies; however, its degradation into peptides and subsequent presentation by MHC class I molecules, such as HLA-A*02:01, allows for recognition by the cellular immune system (Lin et al., 1997). These pMHC complexes are highly specific markers for EBV-transformed cells, making them ideal targets for precision immunotherapies like TCR-engineered T-cells (TCR-T) and TCR-like monoclonal antibodies (Tang et al., 2022). Such therapies aim to overcome the low natural immunogenicity of LMP1 by providing high-affinity synthetic receptors that trigger potent cytotoxic responses against the tumor.

Other names

LMP1-HLA complexEBV LMP1-MHC ILMP1-derived epitope-HLA-A*02:01 complexEpstein-Barr virus LMP1-pMHC

Recognition of the specific viral peptide-MHC complex by engineered T-cell receptors or antibodies to induce targeted lysis of EBV-infected cells.